Health & Environmental Research Online (HERO)


Print Feedback Export to File
5320236 
Journal Article 
FORMULATION AND DEVELOPMENT OF NOVEL INSITU NASAL GEL CONTAINING GLIBENCLAMIDE NANOPARTICLES 
Gohel, MC; Parikh, RK; Patel, KD 
2009 
68-71 
WOS:000273330500020 
In order to provide an alternative, patient compliant and controlled release of sulfonylureas, nasal route is one of the best options among other routes for type-II diabetes mellitus. Glibenclamide (GLB) was selected since its oral absorption is affected by presence of food and it undergoes extensive first-pass metabolism. GLB loaded solid lipid nanoparticles (SLN) were prepared using stearic acid and Poloxamer 188 by hot homogenization technique. Carbomer 934P was incorporated as a gelling agent in the formulation with menthol as nasal decongestant and permeation enhancer. The formulation of pH 6.2-6.4 was optimized using central composite design. The optimized formulation showed drug diffusion of about 90.59% over 24 hours in bio-relevant nasal dissolution test apparatus using saline phosphate buffer pH 6.4 at 34 +/- 0.5 degrees C. Particle size analysis was done using scanning electron microscope (SEM) and it was found in the range of 290-420nm. 
glibenclamide; solid lipid nanoparticles; stearic acid; in-situ nasal gel; controlled release